|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Westin JR, McLaughlin P, Romaguera J,
Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L,
Oki Y, et al: Paclitaxel, topotecan and rituximab: Long term
outcomes of an effective salvage programme for relapsed or
refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol.
167:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh
S, Kim SY, Do YR, Lee H, Lee SI, et al: Clinical outcome and
prognosis of patients with primary sinonasal tract diffuse large
B-cell lymphoma treated with rituximab-cyclophosphamide,
doxorubicin, vincristine and prednisone chemotherapy: A study by
the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma.
56:1020–1026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park JH, Yoon DH, Kim DY, Kim S, Seo S,
Jeong Y, Lee SW, Park CS, Huh J and Suh C: The highest prognostic
impact of LDH among international prognostic indices (IPIs): An
explorative study of five IPI factors among patients with DLBCL in
the era of rituximab. Ann Hematol. 93:1755–1764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen JB, Behera M, Thompson CA and
Flowers CR: Evaluating surveillance imaging for diffuse large
B-cell lymphoma and Hodgkin lymphoma. Blood. 129:561–564. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones K, Nourse JP, Keane C, Bhatnagar A
and Gandhi MK: Plasma microRNA are disease response biomarkers in
classical Hodgkin lymphoma. Clin Cancer Res. 20:253–264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iqbal J, Shen Y, Huang X, Liu Y, Wake L,
Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, et al: Global
microRNA expression profiling uncovers molecular markers for
classification and prognosis in aggressive B-cell lymphoma. Blood.
125:1137–1145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gracias DT, Stelekati E, Hope JL,
Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry
EJ, Turner M and Katsikis PD: The microRNA miR-155 controls CD8(+)
T cell responses by regulating interferon signaling. Nat Immunol.
14:593–602. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huskova H, Korecka K, Karban J, Vargova J,
Vargova K, Dusilkova N, Trneny M and Stopka T: Oncogenic
microRNA-155 and its target PU.1: An integrative gene expression
study in six of the most prevalent lymphomas. Int J Hematol.
102:441–450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeng Q, Tao X, Huang F, Wu T, Wang J,
Jiang X, Kuang Z and Cheng B: Overexpression of miR-155 promotes
the proliferation and invasion of oral squamous carcinoma cells by
regulating BCL6/cyclin D2. Int J Mol Med. 37:1274–1280. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv L, An X, Li H and Ma L: Effect of
miR-155 knockdown on the reversal of doxorubicin resistance in
human lung cancer A549/dox cells. Oncol Lett. 11:1161–1166. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McLaughlin LP, Gottschalk S, Rooney CM and
Bollard CM: EBV-directed T cell therapeutics for EBV-associated
lymphomas. Methods Mol Biol. 1532:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roy Ghosh S, Robertson ES and Saha A:
Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis.
Biomolecules. 6:pii: E46. 2016.
|
|
15
|
Mackrides N, Campuzano-Zuluaga G,
Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, Levy R, Verdun RE,
Kunkalla K, Natkunam Y, et al: Epstein-Barr virus-positive
follicular lymphoma. Mod Pathol. 30:519–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raab-Traub N: EBV-induced oncogenesisHuman
Herpesviruses: Biology, Therapy and Immunoprophylaxis. Arvin A,
Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R and
Yamanishi K: Cambridge University Press 2007; Cambridge: 2007,
View Article : Google Scholar
|
|
17
|
Huang YC, Lin SJ, Lin KM, Chou YC, Lin CW,
Yu SC, Chen CL, Shen TL, Chen CK, Lu J, et al: Regulation of EBV
LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma
and its impact on patients' survival. Blood. 128:1578–1589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen Y, Zhang R, Liu L, Shen Y, Song W, Qi
T, Tang Y, Wang Z, Guan L and Lu H: Clinical and prognostic
analysis of 78 patients with human immuno-deficiency virus
associated non-Hodgkin's lymphoma in Chinese population. Infect
Agent Cancer. 12:72017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mukhtar F, Boffetta P, Risch HA, Park JY,
Bubu OM, Womack L, Tran TV, Zgibor JC and Luu HN: Survival
predictors of Burkitt's lymphoma in children, adults and elderly in
the United States during 2000–2013. Int J Cancer. 140:1494–1502.
2016. View Article : Google Scholar
|
|
21
|
Öztürk E, Özbalak M, Berk S, Erdoğan I,
Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, et
al: Comparison of international prognostic index and NCCN-IPI in
324 patients with de novo diffuse large B-cell lymphoma: A
multi-center retrospective analysis. Leuk Lymphoma. 57:1211–1214.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sesques P and Johnson NA: Approach to the
diagnosis and treatment of high-grade B-cell lymphomas with MYC and
BCL2 and/or BCL6 rearrangements. Blood. 129:280–288. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Y, Zhu T, Zhang P, Xiao M, Yi S, Yang
Y, Li Q, Ling S, Wang Y, Gao L, et al: Mutations or copy number
losses of CD58 and TP53 genes in diffuse large B cell lymphoma are
independent unfavorable prognostic factors. Oncotarget.
7:83294–83307. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zamani-Ahmadmahmudi M, Aghasharif S and
Ilbeigi K: Prognostic efficacy of the human B-cell lymphoma
prognostic genes in predicting disease-free survival (DFS) in the
canine counterpart. BMC Vet Res. 13:172017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Due H, Svendsen P, Bodker JS, Schmitz A,
Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS and Dybkær K: miR-155
as a Biomarker in B-Cell Malignancies. Biomed Res Int.
2016:95130372016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Fu R, Yang L and Tu W: miR-21
expression predicts prognosis in diffuse large B-cell lymphoma. Int
J Clin Exp Pathol. 8:15019–15024. 2015.PubMed/NCBI
|
|
27
|
Jeong D, Kim J, Nam J, Sun H, Lee YH, Lee
TJ, Aguiar RC and Kim SW: MicroRNA-124 links p53 to the NF-κB
pathway in B-cell lymphomas. Leukemia. 29:1868–1874. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang KC, Chen PC, Chang Y, Wu YH, Chen
YP, Lai CH, Medeiros LJ, Su IJ and Wang HW: Epstein-Barr virus
latent membrane protein-1 up-regulates cytokines and correlates
with older age and poorer prognosis in Hodgkin lymphoma.
Histopathology. 70:442–455. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Olszewski AJ, Fallah J and Castillo JJ:
Human immunodeficiency virus-associated lymphomas in the
antiretroviral therapy era: Analysis of the National Cancer Data
Base. Cancer. 122:2689–2697. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paydas S, Acikalin A, Ergin M, Celik H,
Yavuz B and Tanriverdi K: Micro-RNA (miRNA) profile in Hodgkin
lymphoma: Association between clinical and pathological variables.
Med Oncol. 33:342016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monsálvez V, Montes-Moreno S, Artiga MJ,
Rodríguez ME, Sanchez-Espiridion B, Lozano M, Fernández-de-Misa R,
Rodríguez-Peralto JL, Piris MA and Ortíz-Romero PL: MicroRNAs as
prognostic markers in indolent primary cutaneous B-cell lymphoma.
Mod Pathol. 26:171–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lajoie V, Lemieux B, Sawan B,
Lichtensztejn D, Lichtensztejn Z, Wellinger R, Mai S and Knecht H:
LMP1 mediates multinuclearity through downregulation of shelterin
proteins and formation of telomeric aggregates. Blood.
125:2101–2110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bollard CM, Gottschalk S, Torrano V, Diouf
O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, et al:
Sustained complete responses in patients with lymphoma receiving
autologous cytotoxic T lymphocytes targeting Epstein-Barr virus
latent membrane proteins. J Clin Oncol. 32:798–808. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao Y, Zhang DW, Zhu H, Lin H, Xiong L,
Cao Q, Liu Y, Li QD, Xu JR, Xu LF and Chen RJ: LMP1 and LMP2A are
potential prognostic markers of extranodal NK/T-cell lymphoma,
nasal type (ENKTL). Diagn Pathol. 7:1782012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ,
Xia ZJ, Huang HQ, Jiang WQ, Zhang YJ and Wang L: PD-L1 is
upregulated by EBV-driven LMP1 through NF-κB pathway and correlates
with poor prognosis in natural killer/T-cell lymphoma. J Hematol
Oncol. 9:1092016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zuercher E, Butticaz C, Wyniger J,
Martinez R, Battegay M, El Amari Boffi E, Dang T, Egger JF, Fehr J,
Mueller-Garamvögyi E, et al: Genetic diversity of EBV-encoded LMP1
in the Swiss HIV Cohort Study and implication for NF-Κb activation.
PLoS One. 7:e321682012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Knecht H, Berger C, Rothenberger S,
Odermatt BF and Brousset P: The role of Epstein-Barr virus in
neoplastic transformation. Oncology. 60:289–302. 2001. View Article : Google Scholar : PubMed/NCBI
|
